Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by stopping the immune system from rejecting donor stem cells or donor white blood cells.
PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with chronic graft-versus-host disease that is refractory (not responsive) to treatment with steroids.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
OBJECTIVES:
Primary
- Determine the response rate in patients with refractory chronic graft-versus-host disease treated with pentostatin.
Secondary
- Determine the time to next immunosuppressive agent (i.e., the time to progression from best response) in patients treated with this drug.
- Determine the toxicity of this drug in these patients.
- Determine the infection rate in patients treated with this drug.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the changes in lymphocyte populations in patients treated with this drug.
- Determine the survival of patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive pentostatin IV over 20-30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Patients who achieve a complete response after 6 courses receive 4 additional courses. Patients who achieve a partial response, minor response, or stable disease after 6 courses may receive up to 6 additional courses.
Patients are followed every 4 weeks for 1 year, every 3 months for 2 years, and then annually for 5 years.
PROJECTED ACCRUAL: Approximately 37 patients will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Delaware
-
Lewes, Delaware, Stati Uniti, 19958
- Tunnell Cancer Center at Beebe Medical Center
-
Newark, Delaware, Stati Uniti, 19713
- CCOP - Christiana Care Health Services
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, Stati Uniti, 60612-7243
- University of Illinois Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
Elkton, Maryland, Stati Uniti, 21921
- Union Hospital Cancer Program at Union Hospital
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic Cancer Center
-
-
New Jersey
-
Voorhees, New Jersey, Stati Uniti, 08043
- Cancer Institute of New Jersey at Cooper - Voorhees
-
-
New York
-
New York, New York, Stati Uniti, 10021
- New York Weill Cornell Cancer Center at Cornell University
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Stati Uniti, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210-1240
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Stati Uniti, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224-1791
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23298-0037
- Virginia Commonwealth University Massey Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- Histologic documentation of chronic GvHD following allogeneic HCT or donor lymphocyte infusion.
- Patients may have progressive, quiescent, or de novo onset chronic GvHD.
Patients with extensive stage chronic GvHD requiring systemic immunosuppressive therapy are eligible. Patients with limited stage disease are excluded. Extensive stage is defined according to Seattle criteria (9) as either:
- Generalized skin involvement or
Limited skin involvement or hepatic involvement with any one of the following:
- Liver histology showing chronic progressive hepatitis, bridging necrosis or cirrhosis
- Eye involvement (Schirmer's test with < 5 mm wetting)
- Involvement of minor salivary glands or oral mucosa
- Involvement of any other organ
Patients must have failed treatment with, or experience progression after, prior corticosteroids for extensive stage chronic GvHD, as defined below.
4.1 Patients will be considered to have failed corticosteroids if they have any one of the following criteria:
- Progressive disease or less than a minor response in any organ system despite 2 weeks on corticosteroid treatment at least 1 mg/kg methylprednisolone or equivalent.
- Failure to achieve at least a minor response after at least 4 weeks of treatment with a dose of ≥ 0.5 mg/kg methylprednisolone or equivalent.
- Achievement of less than a partial response at 8 weeks of corticosteroid treatment despite use of a dose ≥ 0.5 mg/kg methylprednisolone or equivalent.
- Requirement of ≥ 0.5 mg/kg methylprednisolone or equivalent to maintain a partial response or better at 12 weeks of corticosteroid treatment.
- Requirement of > 10 mg/kg methylprednisolone or equivalent to maintain a partial response or better at 18 weeks of corticosteroid treatment.
4.2 Patients with progression of extensive stage chronic GvHD after a prior history of treatment with at least 18 weeks of corticosteroids, now requiring the reintroduction of corticosteroids (> 10 mg/day methylprednisolone or equivalent) or an additional agent (including photopheresis, PUVA) for treatment.
- Patients with established chronic GvHD not improving or progressing on other immunosuppressive agents are also eligible if steroid refractoriness has been established previously.
- Age ≥ 18 years
- Performance Status 0-3
- Patients on mechanical ventilation are excluded.
- No active infection. Patients with active infection requiring antibiotic therapy are not eligible until infection is controlled.
- No HIV infection. Patients with HIV infection are excluded because of safety concerns in this patient population.
- Non-pregnant and non-nursing. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial (although it is unlikely that successful pregnancy will occur in patients with chronic GvHD). Appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (Norplant®), or double barrier method (diaphragm plus condom).
Required Initial Laboratory Values:
- Calc. Creatinine Clearance ≥ 30 mL/min/1.73 m^2
- ANC > 1000/μL
- Platelets > 50,000/μL without transfusion
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Pentostatin
treatment of pts with refractory graft vs host disease
|
4 mg/sq m IV infusion over 20-30 min q 2 weeks
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Response Rate
Lasso di tempo: 3 months
|
Percentage of participants who had a complete or partial response defined by the Hopkins scoring system. A complete response is defined as the disappearance of signs and symptoms of chronic GVHD in all involved systems that is sustained for at lest 4 weeks. A partial response is an improvement by 2 or more points in at least one system score, which is sustained for at least 4 weeks, with no signs of worsening in others. |
3 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Grade 3 or Higher Non-hematologic Adverse Events
Lasso di tempo: Duration of treatment (up to 5 years)
|
Number of participants experiencing a grade 3, 4 or 5 clinically significant non-hematologic adverse events, at least possibly related to treatment.
|
Duration of treatment (up to 5 years)
|
|
Overall Survival At 1 Year
Lasso di tempo: 1 year
|
Percentage of patients who were alive at 1 year.
|
1 year
|
|
Overall Survival At 2 Years
Lasso di tempo: 2 year
|
Percentage of patients who were alive at 2 years.
|
2 year
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetics Association Between Exposure and Response At 3 Months
Lasso di tempo: 3 months
|
The individual PK parameters will be derived by using a noncompartmental analysis of the plasma-concentration-time data
|
3 months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Cattedra di studio: Sherif S. Farag, MD, PhD, Ohio State University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CALGB-100101
- U10CA031946 (Sovvenzione/contratto NIH degli Stati Uniti)
- CDR0000341678 (Identificatore di registro: NCI Physician Data Query)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .